Overview
Public BiotechPhase 4ketaminepsilocybin
Clinical-stage biopharma developing intranasal pherine therapies for anxiety and depression. Fasedienol in Phase 3 for social anxiety disorder. Novel nose-to-brain neurocircuit approach.
Visit WebsiteSouth San Francisco, CA
$35M
Market Cap
1998
Founded
0
Open Roles
Open Positions
No open positions at this time
Clinical Pipeline(3)
Not Yet Recruiting·Phase 4·ketamine
An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium
Esketamine combined with dexmedetomidineDexmedetomidine
Unknown·Phase 4·ketamine
Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
EsketamineHepatocellular Carcinoma
Unknown·Early Phase 1·psilocybin
A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients
Psilocybin-assisted therapy within a community of practice model (group administered)End of Life